Judging from the number of dietary supplement companies that are being snatched up by heavy-hitting suppliers in the over-the-counter space, the 5% uptick in supplement sales for the 52 weeks ended Aug. 12 is one trend that stands to continue.
The overall foot care category was relatively flat — down 0.9% — with $587.2 million in sales for the 52 weeks ended Aug. 12 across food, drug and mass (excluding Walmart), according to SymphonyIRI Group data. However, almost 2-out-of-3 foot care products sold are insoles, which bodes well for sales going forward.
Over the last few years of DSN’s coverage of the impending patent cliff and how it would affect the generic drug industry, IMS Health VP industry relations Doug Long predicted that the gradual commoditization of primary care drugs — long the lifeblood of generic drug makers — would lead to consolidation of the industry.
It’s a little hard not to say “Oh, how the mighty have fallen” when a retailer announces that it will give away for free what was once the world’s top-selling drug. But for retailers, it also makes good business sense.
For branded drug makers, the pharmaceutical patent cliff has never loomed higher or steeper. The exposure of so many of the world’s biggest-selling medicines to generic competition for the first time is redefining the pricing model for many of the most widely prescribed classes of pharmaceuticals.
A trillion of anything is difficult to wrap one’s head around, whether it’s the number of grains of sand on a beach or stars in the sky. It’s so much easier for the human mind to look at such a quantity as the sum of its parts rather than on the basis of its individual components.
2012 is turning out to be a pretty important year for generic drugs, important enough that some of the things happening over the past several months have begged comparison to 1984, probably the biggest milestone year for the industry.
Cleaning the face of makeup, dirt and other impurities in the morning and night is clearly an important part of a healthy skin care routine, and manufacturers continue to answer the call with products that promise to deliver even greater results.
Acne is the most common skin disorder within the United States, impacting millions of Americans and paving the way for researchers to feverishly develop new therapies and revamp existing treatment options at retail.